Enforcement Report - Week of January 25, 2023
Enforcement Report - Week of September 21, 2022
Enforcement Report - Week of August 24, 2022
Enforcement Report - Week of June 15, 2022
ATHLONE, Ireland--(BUSINESS WIRE)--Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced today positive topline results from Study INN-CB-024, a Phase 3 randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a 300mg dose of XARACOLL, an innovative collagen drug-device implant, in patients undergoing abdominoplasty. Among patients receiving XARACOLL, a reduction in pain intensity and opioid use was observed through 24 hours post-surgery.
Enforcement Report - Week of August 18, 2021
Enforcement Report- Week of June 9, 2021
Hospira Issues A Voluntary Nationwide Recall for One Lot of 0.5% Bupivacaine Hydrochloride Injection
Enforcement Report - Week of December 30, 2020
Enforcement Report - Week of November 18, 2020